Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HURA TuHURA Biosciences	$2.47 -5.4%	$3.10	$1.80 ▼ $7.93	$108.33M	0.17	264,632 shs	603,783 shs
IMRX Immuneering	$3.39 -5.6%	$2.00	$1.00 ▼ $3.87	$124.15M	0.38	2.56 million shs	908,546 shs
INBX Inhibrx Biosciences	$16.29 +3.5%	$13.45	$10.80 ▼ $17.79	$236.39M	-0.04	95,352 shs	53,380 shs
PRQR ProQR Therapeutics	$2.14 +0.6%	$1.81	$1.07 ▼ $4.62	$229.36M	0.36	659,483 shs	175,653 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HURA TuHURA Biosciences	0.00%	+11.26%	-14.53%	-26.92%	+246,999,900.00%
IMRX Immuneering	0.00%	-3.97%	+65.37%	+140.43%	+200.00%
INBX Inhibrx Biosciences	0.00%	+12.86%	+26.34%	+22.08%	+21.17%
PRQR ProQR Therapeutics	0.00%	+5.05%	+19.72%	+81.61%	+30.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HURA TuHURA Biosciences	1.2477 of 5 stars	3.7	0.0	0.0	0.9	0.0	0.0
IMRX Immuneering	4.0924 of 5 stars	3.3	4.0	0.0	4.2	5.0	0.6
INBX Inhibrx Biosciences	1.1931 of 5 stars	0.0	1.0	4.6	0.0	2.5	1.3
PRQR ProQR Therapeutics	2.1281 of 5 stars	3.6	3.0	0.0	2.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HURA TuHURA Biosciences	3.40	Buy	$12.67	412.82% Upside
IMRX Immuneering	2.60	Moderate Buy	$13.25	290.86% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
PRQR ProQR Therapeutics	3.13	Buy	$8.00	273.31% Upside

Current Analyst Ratings Breakdown

Latest IMRX, INBX, PRQR, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
IMRX Immuneering	$320K	381.27	N/A	N/A	$1.33 per share	2.55
INBX Inhibrx Biosciences	$200K	1,178.71	$116.32 per share	0.14	$9.23 per share	1.76
PRQR ProQR Therapeutics	$18.97M	11.88	N/A	N/A	$0.91 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	291.69%	122.09%	N/A
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.14	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)

Latest IMRX, INBX, PRQR, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HURA TuHURA Biosciences	N/A	3.00	3.00
IMRX Immuneering	N/A	7.48	7.48
INBX Inhibrx Biosciences	1.04	5.12	5.12
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HURA TuHURA Biosciences	0.62%
IMRX Immuneering	67.65%
INBX Inhibrx Biosciences	82.46%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
HURA TuHURA Biosciences	0.20%
IMRX Immuneering	22.90%
INBX Inhibrx Biosciences	17.09%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HURA TuHURA Biosciences	N/A	43.68 million	43.59 million	N/A
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.00 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

IMRX, INBX, PRQR, and HURA Headlines

Recent News About These Companies

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3 at 10:39 PM | morningstar.comM

Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00

July 3 at 2:21 AM | americanbankingnews.com

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from Brokerages

June 30, 2025 | marketbeat.com

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics (NASDAQ:PRQR) Earns Market Outperform Rating from JMP Securities

June 29, 2025 | americanbankingnews.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP Securities

June 27, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

Cantor Fitzgerald Comments on PRQR FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)

June 6, 2025 | marketbeat.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

May 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX, INBX, PRQR, and HURA Company Descriptions

TuHURA Biosciences NASDAQ:HURA

$2.47 -0.14 (-5.36%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$2.49 +0.02 (+0.81%)

As of 07/3/2025 04:54 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Immuneering NASDAQ:IMRX

$3.39 -0.20 (-5.57%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$3.38 -0.02 (-0.44%)

As of 07/3/2025 04:59 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Inhibrx Biosciences NASDAQ:INBX

$16.28 +0.55 (+3.46%)

As of 07/3/2025 01:04 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

ProQR Therapeutics NASDAQ:PRQR

$2.14 +0.01 (+0.52%)

As of 07/3/2025 03:59 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time